Board of Directors

Marc Fishman, MD

Executive Chairman

Dr. Fishman founded Oncology Analytics in 2009. As a hematologist, oncologist and patient advocate, Dr. Fishman recognized that the rising costs and complexity of cancer treatment were compromising the ability for oncologists to make comprehensive, evidenced-based decisions for their patients’ treatment.

Dr. Fishman is board-certified in Internal Medicine and Hematology and developed his perspective on healthcare management and funding mechanisms through a wide variety of clinical experiences, including work in Kenya, New Zealand, Canada, Australia, and the United States. Dr. Fishman’s 20+ years of clinical treatment experience and exposure to multi-national health systems has reinforced his commitment to value-based care and a patient first approach, which measures the efficacy, toxicity and affordability of cancer treatment options, which put the patient in a position to achieve the best possible outcome.

Rick Dean

Chief Executive Officer

Rick Dean serves as CEO of Oncology Analytics. Mr. Dean brings more than two decades of experience to Oncology Analytics, including successfully leading and growing innovative healthcare companies through various stages of maturation. Mr. Dean joined Oncology Analytics from Optum, the healthcare services arm of UnitedHealth Group. At Optum, Mr. Dean was a founding member of Optum Ventures, a venture capital fund focused on digital health innovation. Prior to Optum Ventures, he led global sales and growth for Optum Analytics.

Mr. Dean joined Optum after the acquisition of Humedica, a transformative population health and analytics company, where he was the company’s Chief Growth Officer. Prior to Humedica, Mr. Dean was Senior Vice President of North American sales for Sentillion, a highly successful venture-backed healthcare company that was acquired by Microsoft in 2010. Mr. Dean is a past board member of AMGA Analytics, the informatics subsidiary of the American Medical Group Association.

Mr. Dean earned a Bachelor of Science degree in finance from the University of North Carolina.

Annie Lamont

Co-Founder & Managing Partner, Oak HC/FT

Oak HC/FT Co-Founder & Managing Partner, Annie Lamont has more than 30 years of experience as a venture capitalist investing in transformative companies and entrepreneurs.

In 2014, Annie, along with Patricia Kemp and Andrew Adams, launched Oak HC/FT, a venture capital firm that invests in early to growth stage tech-enabled companies shaping the future of healthcare information and financial services. Before founding Oak HC/FT, Annie was a Managing Partner at Oak Investment Partners.

Annie is known as a leading healthcare and fintech investor, appearing on the Forbes Midas List, Institutional Investor’s FinTech Finance 40 list, and the Top 100 Venture Capitalist rankings published by CB Insights and The New York Times. She was the first recipient of the National Venture Capital Association’s award for Excellence in Healthcare Innovation. Annie was also honored with Healthcare Private Equity Association’s 2017 Russell L. Carson Award for lifetime achievement in healthcare investing.

She serves on the board of HCA, one of the world’s leading healthcare companies, and previously served on the Stanford Board of Trustees.

Annie received her bachelor’s degree in political science from Stanford University.

Ezekiel J. “Zeke” Emanuel, M.D. Ph.D.

Venture Partner, Oak HC/FT

A Venture Partner since 2015, Zeke centers on growth equity and early-stage venture opportunities in healthcare information services.

He is the Vice Provost for Global Initiatives at the University of Pennsylvania, where he also is the Diane v.S. Levy and Robert M. Levy University Professor and Chair of the Department of Medical Ethics and Health Policy. In addition, he is a Senior Fellow at the Center for American Progress.

Previously, Zeke, who is a breast oncologist, was an associate professor at Harvard Medical School before joining the National Institutes of Health, where he was the founding chair of the Department of Bioethics. He also served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council.

He received a Bachelor of Science degree in chemistry from Amherst College, a Master of Science degree in biochemistry from Oxford University, a Doctor of Medicine degree from Harvard Medical School and a Ph.D. in political philosophy from Harvard University.

Zeke is the author of several books, including Reinventing American Health Care: How the Affordable Care Act will Improve our Terribly Complex, Blatantly Unjust, Outrageously Expensive, Grossly Inefficient, Error Prone System and Brothers Emanuel: A Memoir of an American Family. He is an op-ed contributor to The New York Times, The Wall Street Journal, Forbes and Fortune and a regular contributor to MSNBC, Fox News and CNN.

He is a member of the Council on Foreign Relations and the chair of the meta-council on the Future of Health Care Committee for the World Economic Forum. He has received numerous awards, including election to the Institute of Medicine of the National Academy of Science, the Association of American Physicians and the Royal College of Medicine. Among other awards, Hippocrates Magazine selected him as Doctor of the Year in Ethics. He is a member of the board of VillageMD.

Thomas Hawes, M.D.

Sandbox Industries

Tom Hawes is a member of the BlueCross BlueShield Fund Management team at Sandbox Industries and serves on the Sandbox Management Committee. He is the Board Chairman for Patientco, serves on the Board of Directors of Octave Bioscience, BehaveCare, and AbleTo and is a board observer of Phreesia, HeartFlow, and Healthify. Before joining Sandbox, Tom matched at Yale School of Medicine for residency and completed his first year of medical training at Greenwich Hospital. During his medical training, he worked on clinical studies at the ISK Institute for Orthopaedics and Sports Medicine and on outcomes research at the National Cancer Institute and NYMC’s Cardiothoracic Surgery Department. Tom holds a BA from Brigham Young University, an M.D. from New York Medical College and an MBA from Harvard Business School. He is also a Kauffman Fellow.

Michael Weintraub

Michael was most recently Managing Partner of Optum Ventures, a leading health services company focused on digital health innovation. He also co-founded and served as CEO of Humedica, a pioneer and leader in the field of population health management and big data. In 2013, Humedica was acquired by UnitedHealth Group (UHG), and he broadened his role within the company to become President and CEO of Optum Analytics. Prior to launching Humedica, Michael served as Senior Managing Director at Leerink Partners, a leading healthcare investment bank. Michael was also President and CEO of PHARMetrics, a healthcare informatics company, which was acquired by IMS Health, now IQVIA, in 2005.

He serves as Founding Chairman of the Board of Phreesia, a NYC based healthcare software company that focuses on a point-of-service platform which includes patient self-service and mobile applications. Michael also serves as the Chairman of the Board of BroadReach, a global healthcare company headquartered in Cape Town, South Africa. He is an Entrepreneur in Residence at Harvard Business School, focused on healthcare innovation, and a mentor and speaker at the Harvard Innovation Lab (iLab), a unique collaboration and education space designed to foster entrepreneurship. Michael is an advisor at the GLG Institute, a community of senior executives exchanging leadership and operational experience. He is also an Advisory Board member of the Innovation and Digital Health Accelerator at Boston Children’s Hospital. Michael is a member of the Board of Directors of The College Diabetes Network (CDN), whose mission is to empower and improve the lives of students living with Type 1 diabetes through peer support and access to information and resources. Michael received his MBA from Harvard Business School and earned his bachelor’s degree in Economics from Brandeis University.

Peter B. Bach, M.D., MAPP

Director, Memorial Sloan Kettering’s Center for Health Policy and Outcomes

Dr. Bach is a physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients.

Dr. Bach has published more than 100 peer-reviewed articles and editorials in scientific journals such as the New England Journal of Medicine and the Journal of the American Medical Association. He has also written numerous healthcare-related op-eds and been featured in mainstream media outlets such as the New York Times, New York magazine, the Wall Street Journal, Forbes, NPR, and 60 Minutes.

Subscribe To Our Newsletter

Join our monthly mailing list to receive the latest news and updates from Oncology Analytics.

You have Successfully Subscribed!